Evolving Landscape of Good Clinical Practice in Clinical Trials: Challenges and Future Perspectives

Nitesh Prasad Sah[1], Shivani[2], Himanshu Yadav[3]

[1] Fortis Healthcare Research Foundation, Gurugram, Haryana, India Department of Clinical Research, Fortis Flt. Lt. Rajan Dhall Hospital, New Delhi 110070

[2]Department of Rheumatology, All India Institute of Medical Science New Delhi 110029

[3] Department of Quality assurance, Biosite Research Bangalore 560078

DOI: https://doi.org/10.51244/IJRSI.2026.1305000077

Received: 06 May 2026; Accepted: 11 May 2026; Published: 29 May 2026

ABSTRACT

Good Clinical Practice (GCP) serves as the ethical and scientific foundation for conducting clinical trials involving human participants. Over the last decade, clinical research has undergone remarkable transformation due to globalization, technological advancement, decentralized trial models, and evolving regulatory expectations. Modern clinical trials increasingly rely on digital technologies, electronic data systems, artificial intelligence, and remote patient monitoring, creating both opportunities and challenges for researchers and regulatory authorities. Key concerns include increasing protocol complexity, participant safety, informed consent in digital environments, data integrity, cybersecurity, and harmonisation of international regulations. Recent updates in International Council for Harmonisation (ICH) guidelines, particularly ICH E6(R3), emphasize risk-based quality management and patient-centered approaches to clinical research. This review discusses the current challenges in implementing GCP, recent regulatory developments, and future perspectives shaping contemporary clinical trials. Understanding these evolving trends is essential for ensuring ethical conduct, regulatory compliance, and high-quality clinical research.

Keywords: Good Clinical Practice; Clinical Trials; Research Ethics; Regulatory Affairs; ICH-GCP; Patient Safety; Informed Consent; Clinical Research; Regulatory Compliance; Digital Clinical Trials

INTRODUCTION

Good Clinical Practice (GCP) is an internationally recognized ethical and scientific standard for the design, conduct, documentation, recording, and reporting of clinical trials involving human participants. The primary purpose of GCP is to ensure the protection of participant rights, safety, dignity, and well-being while maintaining the credibility and integrity of clinical trial data (1).

The concept of ethical clinical research originated from historical ethical frameworks such as the Nuremberg Code, the Declaration of Helsinki, and the Belmont Report. These principles later formed the basis for the International Council for Harmonisation (ICH) guideline for Good Clinical Practice, introduced in 1996 as a unified international standard for clinical research conduct (2).

Over the past decade, the landscape of clinical research has evolved considerably. Clinical trials have become increasingly multinational, technologically advanced, and data-driven. Digital health technologies, electronic health records, wearable devices, decentralized clinical trial models, and artificial intelligence are now widely integrated into research activities. While these innovations have improved efficiency and accessibility in clinical research, they have also introduced significant ethical, operational, and regulatory challenges (3).

In recent years, regulatory authorities and research organizations have placed increasing emphasis on patient-centered approaches, risk-based monitoring, data transparency, and flexible trial management systems. The

modernization of ICH E6(R3) reflects the growing need to adapt GCP principles to the changing clinical research environment (4).

This review aims to discuss the evolving landscape of Good Clinical Practice in modern clinical trials, with particular focus on current challenges, ethical considerations, regulatory developments, and future perspectives.

METHODOLOGY

This narrative critical review was conducted using literature published between 2021 and 2026 indexed in PubMed, Scopus, Web of Science, and Google Scholar. Keywords included “Good Clinical Practice”, “clinical trials”, “decentralized trials”, “artificial intelligence”, “digital health”, and “clinical research ethics”. Inclusion criteria comprised peer-reviewed articles, systematic reviews, regulatory guidelines, and policy documents related to clinical trials and Good Clinical Practice. Studies not published in English, opinion blogs, and non-peer-reviewed sources were excluded. The selected literature was critically analyzed to identify emerging trends, regulatory developments, and ethical challenges in modern clinical trial conduct.

Evolution of Good Clinical Practice

The development of Good Clinical Practice has been closely linked to the evolution of research ethics and international regulatory standards. Following unethical human experimentation during the twentieth century, several ethical frameworks were introduced to protect research participants. The Declaration of Helsinki established ethical principles for medical research involving human subjects and remains one of the most influential documents in clinical research ethics (5).

The International Council for Harmonisation introduced the ICH-GCP guideline to standardize clinical trial conduct across different countries and regulatory systems. The guideline provided a unified framework for investigators, sponsors, ethics committees, and regulatory authorities to ensure participant protection and data reliability (1).

Modern clinical trials differ substantially from traditional research models. Contemporary studies frequently involve multinational collaboration, adaptive trial designs, biomarker-driven therapies, and personalized medicine approaches. Clinical trials also increasingly utilize electronic data capture systems, remote monitoring technologies, and digital communication platforms. These developments have improved research efficiency but have simultaneously increased operational complexity and regulatory demands (6).

To address these emerging challenges, regulatory agencies such as the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) have updated guidance documents focusing on risk-based quality management, participant safety, and digital compliance (7).

The recent draft version of ICH E6(R3) represents a significant modernization of GCP by emphasizing flexibility, proportional oversight, critical-to-quality factors, and technology-enabled trial conduct (4).

Current Challenges in Good Clinical Practice Increasing Complexity of Clinical Trials

Clinical trials have become increasingly complex over the past decade due to advancements in biomedical science and precision medicine. Modern studies often involve large multinational collaborations, adaptive protocols, genomic biomarkers, and highly specialized therapeutic interventions.

Although these innovations improve scientific precision, they also increase the complexity of protocol implementation and regulatory oversight. Complex study procedures may lead to higher rates of protocol deviations, increased operational burden, and difficulties in maintaining compliance with GCP requirements (8).

Furthermore, extensive data collection requirements and complicated eligibility criteria can negatively affect participant recruitment and retention.

Table 1: Major Challenges in Good Clinical Practice (GCP)

Domain	Key Challenges	Impact on Clinical Trials
Protocol Complexity	Increasing multicenter, adaptive, and precision-based trial designs	Higher protocol deviations, operational burden, delayed completion
Ethical Issues	Vulnerable populations, fairness in recruitment, risk–benefit imbalance	Ethical review difficulties, variability across regions
Informed Consent	Use of electronic consent and complex medical information	Reduced understanding, digital literacy barriers
Data Integrity	Electronic data systems, cloud storage, wearable devices	Risk of data breaches and manipulation
Regulatory Variability	Differences in global regulatory requirements	Delays in approvals, increased compliance burden
Decentralized Trials	Remote monitoring and home-based assessments	Limited investigator oversight and validation challenges

Ethical Challenges in Clinical Research

Ethical considerations remain central to the implementation of Good Clinical Practice. Ensuring participant safety and maintaining ethical integrity have become more challenging in increasingly complex and technology-driven research environments.

Important ethical concerns include protection of vulnerable populations, equitable participant selection, fair risk–benefit assessment, privacy protection, and transparency in data handling. Researchers must ensure that participants fully understand study procedures, potential risks, and expected benefits before enrollment (9).

The globalization of clinical trials has also introduced ethical variability across countries with different healthcare systems, cultural values, and regulatory structures. Maintaining consistent ethical standards across multinational studies continues to be a significant challenge.

Challenges in Informed Consent

Informed consent is a fundamental principle of ethical clinical research. Traditionally, informed consent involved face-to-face discussion and written documentation. However, digital technologies have transformed the consent process through electronic informed consent (eConsent) systems.

Electronic consent platforms may improve accessibility, participant engagement, and documentation efficiency. Despite these advantages, concerns remain regarding participant comprehension, digital literacy, data confidentiality, and regulatory acceptance (10).

In highly technical clinical trials, participants may struggle to fully understand complex scientific information. Ensuring voluntary participation and meaningful understanding remains essential for ethical compliance.

Data Integrity and Cybersecurity

Modern clinical trials increasingly depend on electronic systems, cloud-based platforms, wearable devices, and remote monitoring technologies for data collection and management. While these tools improve efficiency and real-time monitoring, they also create new risks related to cybersecurity and data integrity.

Potential concerns include data breaches, unauthorized access, electronic record manipulation, and inadequate system validation. Regulatory authorities now place substantial emphasis on audit readiness, electronic system validation, and secure data governance practices (11).

Maintaining accurate, reliable, and traceable research data has become a critical component of GCP compliance.

Regulatory Variability Across Countries

The globalization of clinical trials has increased the need for international regulatory harmonisation. However, differences still exist in ethics review procedures, approval timelines, documentation requirements, and safety reporting systems among various countries.

Lack of regulatory harmonisation may delay study initiation, increase administrative burden, and complicate multinational trial management (12). Researchers and sponsors conducting global trials must comply with multiple regulatory frameworks simultaneously, which often increases operational costs and complexity.

Impact of Decentralized Clinical Trials

Decentralized clinical trials (DCTs) gained significant attention during the COVID-19 pandemic. These trials utilize telemedicine, remote patient monitoring, wearable devices, and home-based assessments to reduce participant burden and improve accessibility (13).

Decentralized models may improve participant recruitment, retention, and geographic diversity. However, they also present challenges related to investigator oversight, source data verification, technology reliability, and regulatory compliance.

Ensuring participant safety and maintaining consistent trial quality in remote settings remain important concerns for regulators and investigators.

Regulatory Developments in Good Clinical Practice ICH E6(R3) Modernization

The updated ICH E6(R3) guideline represents one of the most important recent developments in Good Clinical Practice. The revised framework focuses on risk-based quality management, proportional oversight, and flexibility in trial conduct.

The guideline encourages sponsors and investigators to identify critical-to-quality factors and implement targeted risk management strategies throughout the clinical trial lifecycle (4).

ICH E6(R3) also supports the integration of innovative technologies while maintaining participant safety and data reliability.

Risk-Based Monitoring

Traditional monitoring approaches relied heavily on routine on-site visits and source data verification. However, modern clinical research increasingly uses risk-based monitoring (RBM) strategies.

Risk-based monitoring focuses on identifying critical study risks and utilizing centralized monitoring systems to improve efficiency and resource allocation (14). This approach reduces unnecessary workload while maintaining data quality and participant protection.

Regulatory authorities now widely support RBM as part of modern GCP implementation.

Patient-Centered Clinical Trials

Patient-centered research has become an important component of contemporary clinical trial design. Increasingly, patients are involved in protocol development, endpoint selection, and study planning processes.

Patient engagement may improve recruitment, participant retention, treatment adherence, and overall trial relevance (15). Regulatory agencies now encourage greater incorporation of patient perspectives into clinical research activities.

Global Disparities in Good Clinical Practice Implementation

Significant disparities exist in the implementation of Good Clinical Practice (GCP) across high-income and low- and middle-income countries. While developed countries have advanced digital infrastructure, regulatory systems, and trained clinical research professionals, many developing regions continue to face limitations in these areas. Challenges include inadequate digital health infrastructure, limited access to electronic data capture systems, insufficient training in GCP and digital clinical trial methodologies, and slower regulatory approval processes. Additionally, the adoption of decentralized clinical trials and artificial intelligence-based tools remains limited due to cost and technical constraints. These disparities may result in unequal participation in global clinical research and reduced representation of diverse populations in clinical trials, ultimately affecting the generalizability of research outcomes. Strengthening capacity building, regulatory harmonisation, and international collaboration is essential to address these gaps.

Role of Artificial Intelligence and Digital Technologies

Artificial intelligence (AI) and digital technologies are transforming modern clinical research. AI applications in clinical trials include participant recruitment, predictive analytics, pharmacovigilance, image interpretation, and automated data analysis.

Artificial intelligence has the potential to improve trial efficiency, accelerate decision-making, and optimize operational workflows. However, concerns remain regarding algorithm transparency, bias, accountability, and ethical oversight (16).

Digital health technologies, wearable devices, and electronic patient-reported outcomes have also expanded opportunities for remote monitoring and real-world evidence generation.

Despite these advantages, regulatory frameworks governing AI integration in clinical trials are still evolving. Despite the advantages of artificial intelligence in clinical trials, its real-world implementation raises unresolved ethical and regulatory concerns. Issues such as algorithmic bias, lack of transparency in machine learning models, and limited external validation in diverse populations remain significant challenges. Furthermore, the absence of clear accountability frameworks for AI-driven decision-making in clinical trials raises concerns regarding patient safety and data integrity. These challenges are more pronounced in resource-limited settings where regulatory oversight and technical expertise may be insufficient.

For example, during decentralized clinical trials conducted in the COVID-19 era, reliance on remote monitoring systems highlighted issues related to data quality variability and limited investigator oversight. Similarly, studies using AI-based imaging tools have demonstrated potential diagnostic bias when trained on non-representative datasets, leading to reduced accuracy in underrepresented populations.

Future Perspectives

The future of Good Clinical Practice is expected to focus on greater flexibility, digital integration, and global regulatory collaboration. Hybrid and decentralized clinical trial models are likely to become increasingly common in future research.

Emerging priorities in GCP include:

- Greater international regulatory harmonisation
- Integration of AI governance frameworks
- Advanced cybersecurity and data protection systems

- Expansion of real-world evidence generation
- Improved patient engagement strategies
- Enhanced transparency in clinical research

Training investigators and research staff in digital competencies, ethical decision-making, and regulatory compliance will become increasingly important.

Future GCP frameworks must balance innovation with participant safety, ethical responsibility, and scientific integrity.

Table 2: Future Perspectives in Good Clinical Practice:

Area	**Future Development**	**Expected Benefit**
Regulatory Harmonisation	Alignment of global GCP standards (ICH E6 R3)	Simplified multinational trials
Artificial Intelligence	AI-driven recruitment, monitoring, and analysis	Faster and more efficient trials
Risk-Based Monitoring	Shift from full monitoring to targeted risk approaches	Cost reduction and better efficiency
Decentralized Clinical Trials	Hybrid and fully remote trial models	Improved patient access and retention
Patient-Centered Trials	Increased patient involvement in design	Better recruitment and real-world relevance

CONCLUSION

Good Clinical Practice continues to evolve in response to rapid scientific advancement, technological innovation, and changing healthcare needs. Contemporary clinical trials offer new opportunities for improving patient care and accelerating medical innovation; however, they also introduce substantial ethical, operational, and regulatory challenges.

Maintaining participant safety, ensuring data integrity, strengthening cybersecurity, and adapting regulatory systems to emerging technologies remain critical priorities in modern clinical research. Recent developments such as ICH E6(R3), risk-based monitoring, decentralized clinical trials, and patient-centered research approaches are reshaping the future of clinical trial conduct.

A balanced integration of innovation, ethical responsibility, and regulatory compliance will be essential for ensuring reliable, transparent, and patient-centered clinical research in the future.

REFERENCES

1. International Council for Harmonisation. ICH Harmonised Guideline for Good Clinical Practice E6(R2). 2016.
2. **Vijayananthan A, Nawawi O.** The importance of Good Clinical Practice guidelines and its role in clinical trials. *Biomed Imaging Interv J.* 2008;4(1): e5.
3. **Umscheid CA, Margolis DJ, Grossman CE**. Key concepts of clinical trials. *Clin Transl Sci.* 2011;4(5):367–371.
4. International Council for Harmonisation. ICH E6(R3) Draft Guideline for Good Clinical Practice. 2023.
5. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. 2013.

6. **Getz KA, Campo RA.** Trial complexity and clinical research performance. *Am J Ther.* 2017;24(6): e679–e685.
7. **U.S. Food and Drug Administration**. Risk-Based Monitoring Guidance for Industry. 2019.
8. **Getz KA.** Protocol complexity and clinical trial execution challenges. *Drug Inf J.* 2015;49(4):451–457.
9. **Kadam RA**. Informed consent process: A step further towards making it meaningful. *Perspect Clin Res.* 2017;8(3):107–112.
10. **Grady C, et al**. Broad consent for research with biological samples. *N Engl J Med.* 2015; 372:195–197.
11. U.S. Food and Drug Administration. Data Integrity and Compliance with CGMP Guidance for Industry. 2018.
12. **Singh JA, et al**. Ethics review of multicenter clinical trials: Challenges and opportunities. *Clin Investig.* 2019;9(2):45–52.
13. **Izmailova ES, Ellis R, Benko C**. Remote monitoring in clinical trials during the COVID-19 pandemic. *Clin Transl Sci.* 2020;13(5):838–841.
14. **TransCelerate BioPharma Inc.** Risk-Based Monitoring Methodology. 2017.
15. **Crocker JC, et al**. Patient and public involvement in clinical trial design and conduct. *BMJ.* 2018;363: k4738.
16. **Yu KH, Beam AL, Kohane IS**. Artificial intelligence in healthcare. *Nat Biomed Eng.* 2018; 2:719–731.